These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17074149)

  • 1. [Evaluation of first phase insulin secretion by a nateglinide-intravenous glucose insulin release test in newly diagnosed type 2 diabetics].
    Luo GC; Liang Z; Hu QH; Chai J; Li MZ; Yan DW; Li HY
    Zhonghua Nei Ke Za Zhi; 2006 Aug; 45(8):646-9. PubMed ID: 17074149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
    Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
    Uto Y; Teno S; Iwamoto Y; Omori Y; Takizawa T
    Metabolism; 2002 Jan; 51(1):20-4. PubMed ID: 11782867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.
    Whitelaw DC; Clark PM; Smith JM; Nattrass M
    Diabet Med; 2000 Mar; 17(3):225-9. PubMed ID: 10784228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early insulin release effectively improves glucose tolerance: studies in two rodent models of type 2 diabetes mellitus.
    de Souza CJ; Gagen K; Chen W; Dragonas N
    Diabetes Obes Metab; 2001 Apr; 3(2):85-95. PubMed ID: 11298730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
    Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
    Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.
    Lindsay JR; McKillop AM; Mooney MH; O'Harte FP; Flatt PR; Bell PM
    Diabetes Res Clin Pract; 2003 Sep; 61(3):167-73. PubMed ID: 12965106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide.
    McClenaghan NH; Flatt PR; Ball AJ
    J Endocrinol; 2006 Sep; 190(3):889-96. PubMed ID: 17003289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
    Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
    Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.
    Johanson EH; Jansson PA; Gustafson B; Sandqvist M; Taskinen MR; Smith U; Axelsen M
    Diabetes Metab Res Rev; 2005; 21(4):376-81. PubMed ID: 15724236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
    Hirose T; Mizuno R; Yoshimoto T
    Endocr J; 2002 Dec; 49(6):649-52. PubMed ID: 12625415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of glimepiride and nateglinide on serum insulin and glucose concentration in healthy cats.
    Mori A; Lee P; Yamashita T; Nishimaki Y; Oda H; Saeki K; Miki Y; Mizutani H; Ishioka K; Honjo T; Arai T; Sako T
    Vet Res Commun; 2009 Dec; 33(8):957-70. PubMed ID: 19728131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.
    Mori Y; Kitahara Y; Miura K; Tajima N
    Endocrine; 2004 Feb; 23(1):39-43. PubMed ID: 15034195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
    Uchino H; Niwa M; Shimizu T; Nishiyama K; Kawamori R
    Endocr J; 2000 Oct; 47(5):639-41. PubMed ID: 11200947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading: results of glucose loading on 2 consecutive days.
    Mori Y; Mamori S; Tajima N
    Diabetes Obes Metab; 2005 Mar; 7(2):182-8. PubMed ID: 15715891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapies for newly-onset diabetic patients].
    Kawamori R
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
    [No Abstract]   [Full Text] [Related]  

  • 18. [Preclinical studies of AY4166 (A-4166)].
    Kondo N
    Nihon Rinsho; 1997 Nov; 55 Suppl():159-63. PubMed ID: 9434461
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
    Mori Y; Kitahara Y; Miura K; Mine T; Tajima N
    Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
    Shigeto M; Katsura M; Matsuda M; Ohkuma S; Kaku K
    J Pharmacol Exp Ther; 2007 Jul; 322(1):1-7. PubMed ID: 17409272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.